Cantor Fitzgerald reaffirmed its Overweight rating and $170.00 price target on Ascendis Pharma (NASDAQ:ASND) shares, currently trading at $119.49. The firm's analyst highlighted the early adoption of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback